Nasal insulin will not protect at-risk kids from diabetes, says study
24 Sep 2008

Nasally-administered insulin will not protect children at high risk of developing Type 1 diabetes from the condition, according to researchers from Finland.

A study by staff at the University of Turku, in the south-west of the country, saw 264 children with an increased genetic risk of the disease who tested positive for two or more autoantibodies associated with diabetes in consecutive blood samples.

Nasally-administered insulin was given to 137 children for a median of 1.8 years, while 127 received a placebo.

A total of 56 children in the insulin group eventually developed the condition, in comparison to 53 in the placebo condition, the Washington Post reports.

Drs Kirsti Nanto-Salonen and Olli Simell from the academic institution said: "Administration of nasal insulin did not delay or prevent Type 1 diabetes in children with genetically conferred risk of disease, even when started soon after antibodies to the condition were detected."

The study is expected to be printed in an upcoming edition of the Lancet after being published online.

Login and visit the Diabetes Knowledge Centre

Print Article    Bookmark

• Porridge could limit type-2 diabetes side effects 09/01/09
• Men with type-2 diabetes at greater risk of cardiovascular death 06/01/09
• Decline in mental processing affects diabetes patients, study reveals 05/01/09
• Leptin study could lead to new diabetes treatment 23/12/08
• Symptomless virus linked with type 1 diabetes 19/12/08

• PRANDIN Tablets - 49.44%
  ... in patients with Type 2 diabetes (Non Insulin-Dependent Diabetes Mellitus (NIDDM)) whose hyperglycaemia can no longer be controlled satisfactorily by diet, weight reduction and exercise. Repaglinide is also indicated in combination with metformin in Type 2 diabetes patients who are not ...
  
  
• DDAVP - 49.42%
  ... and treatment of vasopressin-sensitive cranial diabetes insipidus; establishing renal concentration capacity. DDAVP Tablets: Treatment of vasopressin-sensitive cranial diabetes insipidus; treatment of post-hypophysectomy polyuria/ polydipsia. DDAVP/Desmopressin Injection: Cranial diabetes insipidus ...
  
  
• JANUVIA Film-Coated Tablets - 47.95%
  JANUVIA is indicated in patients with type 2 diabetes mellitus to improve glycaemic control in combination with metformin when diet and exercise, plus metformin do not provide adequate glycaemic control. For patients with type 2 diabetes mellitus in whom use of a PPAR? agonist (i.e. a ...
  
  
• EXUBERA - 47.95%
  ... for the treatment of adult patients with type 2 diabetes mellitus not adequately controlled with oral antidiabetic agents and requiring insulin therapy. EXUBERA is also indicated for the treatment of adult patients with type 1 diabetes mellitus, in addition to long or intermediate acting ...
  
  
• NOCUTIL - 47.95%
  Treatment of idiopathic central diabetes insipidus, or diabetes insipidus occurring after hypophysectomy, cranial trauma, or surgery in the pituitary region ...
  
  
• GLUCOPHAGE - 47.95%
  Non-insulin dependent (type II) diabetes either alone or with sulphonylureas. Adjuvant therapy in insulin-dependent diabetes, particularly in the obese ...